EUVIMEDSkopri EUVIMED
Klinische Studie

[ 99m Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study

Yining Sun, Zhixin Hao, Hannan Gao, Guangjie Yang, Bo Pan, Min Zhu, Yakun Wan, Jiyun Shi, Li Huo, Haojun Chen, Fan Wang

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268564 ↗

At a glance

Klinische Studie in Journal of Nuclear Medicine, 2025. Written by Yining Sun and 10 co-authors. Institution: Key Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, C…. Major MEDLINE topics: Antigens, Neoplasm, Cell Adhesion Molecules, Single Photon Emission Computed Tomography Computed Tomography, Tomography, Emission-Computed, Single-Photon. Cited 19 times so far (Crossref); 32 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The trophoblast cell-surface antigen 2 (Trop2) is markedly overexpressed in breast cancers, with a particularly high incidence in triple-negative breast cancer. The therapeutic relevance of Trop2 expression is underscored by the approval of an antibody-drug conjugate for triple-negative breast cancer treatment. However, there is no a predictive technique for accurate whole-body mapping of Trop2 expression in patients. In this study, we developed a novel Trop2-specific molecular probe, [99mTc]Tc-MY6349, and evaluated its safety and feasibility for detecting Trop2 expression in breast cancer using SPECT/CT imaging. Methods: Trop2 expression in different breast cancer cell lines was assessed via immunofluorescence and flow cytometry. The Trop2-specific nanobody MY6349 was site-specifically labeled with 99mTc via a C-terminal GGGC tag, and its binding affinity to the Trop2 receptor was tested in vitro. The in vivo tumor uptake and distribution of [99mTc]Tc-MY6349 were examined through SPECT imaging and biodistribution studies. Furthermore, a pilot clinical study of [99mTc]Tc-MY6349 SPECT/CT was conducted in 8 patients with breast cancer, and the results were compared with [18F]FDG PET/CT. Results: [99mTc]Tc-MY6349 achieved a greater than 95% radiochemical purity after purification. In vitro and in vivo experiments demonstrated the binding specificity of [99mTc]Tc-MY6349 to the Trop2 receptor. In vivo imaging and biodistribution studies revealed a significant correlation between tumor uptake and Trop2 expression levels. In the pilot clinical study, SPECT imaging with [99mTc]Tc-MY6349 successfully detected Trop2-positive tumors 15 min after tracer injection. Delayed imaging showed reduced uptake in normal organs but sustained retention of [99mTc]Tc-MY6349 in tumors. Importantly, [99mTc]Tc-MY6349 SPECT/CT imaging highlighted Trop2 expression heterogeneity and visualized primary and metastatic lesions with a favorable tumor-to-background ratio in breast cancer. Conclusion: [99mTc]Tc-MY6349 was successfully prepared and exhibited a high binding affinity and Trop2 specificity. The pilot clinical study validated the safety and feasibility of [99mTc]Tc-MY6349 SPECT/CT for detecting Trop2 expression in vivo in patients with breast cancer. This imaging modality could complement existing methods, aiding in the guidance of Trop2-targeted therapies and advancing personalized treatment while also promoting the application of SPECT/CT nuclear medicine imaging technology.

Subjects

MeSH terms (MEDLINE)

Antigens, NeoplasmCell Adhesion MoleculesSingle Photon Emission Computed Tomography Computed TomographyTomography, Emission-Computed, Single-PhotonOrganotechnetium CompoundsHumansPilot ProjectsFemaleAnimalsMiceCell Line, TumorTissue DistributionBreast NeoplasmsMiddle Aged

Author keywords

99mTc probeSPECT/CTTrop2breast cancertheranostics

Substances

TACSTD2 protein, humanAntigens, NeoplasmCell Adhesion MoleculesOrganotechnetium Compounds

Authors and institutions

  • Key Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Disease Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking…
  • Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Shanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai, China.
  • Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, China; and.

Cite

APA

Sun, Y., Hao, Z., Gao, H., Yang, G., Pan, B., Zhu, M., Wan, Y., Shi, J., Huo, L., Chen, H., & Wang, F. (2025). [ 99m Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268564

Vancouver

Sun Y, Hao Z, Gao H, Yang G, Pan B, Zhu M, et al. [ 99m Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268564

BibTeX
@article{Sun2025,
  author = {Sun, Yining and Hao, Zhixin and Gao, Hannan and Yang, Guangjie and Pan, Bo and Zhu, Min and Wan, Yakun and Shi, Jiyun and Huo, Li and Chen, Haojun and Wang, Fan},
  title = {[ 99m Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268564}
}
Start for free →